Luxturna™ (voretigene neparvovec)

Last Review Date: December 30, 2020   Number: MG.MM.PH.43

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Luxturna (voretigene neparvovec) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Luxturna (voretigene neparvovec) is designed to deliver a normal copy of the gene encoding the human retinal pigment epithelial 65 kDa protein (RPE65) to cells of the retina in persons with reduced or absent levels of biologically active RPE65. RPE65 is produced in the retinal pigment epithelial (RPE) cells and converts all-trans-retinol to 11-cis-retinal, which subsequently forms chomophore, 11-cis-retinal, during the visual (retinoid) cycle. The visual cycle is critical in phototransduction, which refers to the biological conversion of a photon of light into an electrical signal in the retina. Mutations in the RPE65 gene lead to reduced or absent levels of RPE65 isomeroxydrolase activity, blocking the visual cycle and resulting in impairment of vision. Luxturna (voretigene neparvovec) is intended to negate the effects of mutations in the RPE65 gene.

Guideline

Provider must submit documentation (which may include office notes and lab results) supporting that the patient has met all approval criteria.

Luxturna may be considered medically necessary when all the below criteria are met:

- The patient is between 12 months and 65 years of age; AND
- The patient has a confirmed diagnosis of a biallelic RPE65 mutation-associated retinal dystrophy; AND
- The patient must have documented genetic testing to confirm mutation in both copies of the RPE65 gene; AND
- The member must have sufficient viable retinal cells as determined by treating physician through optical coherence tomography (OCT) imaging and/or ophthalmoscopy indicating:
  - An area of retinal thickness >100 microns within the posterior pole; OR
Luxturna™ (Voretigene neparvovec)

Last review: December 30, 2020

Page 2 of 3

- ≥ 3-disc areas of the retina without atrophy or pigmentary degeneration within the posterior pole; OR
- Any remaining visual field within 30° of fixation as measured by III4e isopter or equivalent; AND

- The patient has not had intraocular surgery within the past six months; AND
- The patient has not used prescription retinoid compounds or precursors within the past 3 months; AND
- Luxturna (voretigene neparvovec) therapy must be prescribed and administered by an ophthalmologist or retinal surgeon at an Ocular Gene Therapy Treatment Center authorized by Spark Therapeutics; AND
- Patient has not previously received subretinal administration of a gene therapy vector, or Luxturna into the intended eye; AND
- The patient will avoid air travel, scuba diving, and/or travel to high elevations until the dissipation of the air bubble formed following administration of Luxturna (voretigene neparvovec) has been verified through ophthalmic examination; AND
- There are no preexisting eye conditions or complicating systemic diseases (e.g. radiotherapy of the orbit, leukemia with CNS/optic nerve involvement, advanced retinopathy patients particularly those with diabetes or sickle cell disease, and immunodeficient patients)

Limitations/Exclusions

- Approval will be granted for 3 months or as determined through review
- Coverage cannot be renewed; a maximum of 1 injection per eye per lifetime will apply
- Use in infants under 12 months of age
- The individual is not pregnant or breastfeeding
- The recommended dose of Luxturna (voretigene neparvovec) for each eye is 1.5 X 10¹¹ vector genomes administered by sub-retinal injection in a total volume of 0.3ml
- If both eyes are to be treated, Luxturna (voretigene neparvovec) must be administered to each eye on separate days at least 6 days apart

Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/30/2020</td>
<td>Annual review: no policy changes</td>
</tr>
<tr>
<td>10/31/2019</td>
<td>Added criteria surrounding preexisting eye conditions or complicating systemic diseases. Added limitation: The individual is not pregnant or breastfeeding.</td>
</tr>
<tr>
<td>07/26/2018</td>
<td>Added coverage to all lines of business</td>
</tr>
<tr>
<td>07/26/2018</td>
<td>Added J3398 and removed J3490, J3590, C9399 from Applicable Procedure Codes.</td>
</tr>
</tbody>
</table>

Applicable Procedure Codes

- J3398 Injection, voretigene neparvovec-ryzl, 1 billion vector genomes

Applicable ICD-10 Codes

- H35.50 Unspecified hereditary retinal dystrophy
- H35.52 Pigmentary retinal dystrophy
- H35.54 Dystrophies primarily involving the retinal pigment epithelium

References

2. FDA Advisory Committee Briefing Document: Spark Therapeutics, INC, Luxturna (voretigene
neparvopec).2017;  
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesand
OtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM579300.pdf Accessed April 10,
2018.

3. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvopec (AAV2-hRPE65v2) in
patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3